Prot #MK-3475-B21: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curati

Project: Research project

Project Details

Effective start/end date5/11/225/11/25


  • Gynecologic Oncology Group (Prot #MK-3475-B21)
  • Merck Sharp & Dohme LLC (Prot #MK-3475-B21)